tbuckley/cabot-search huggingface dataset:
337P Real-life second-line therapies outcome in metastatic pancreatic cancer (mPDAC) patients previously treated with gemcitabine plus nab-paclitaxel (Gem-Nab): An Italian multicenter study
Authors: L. Procaccio, G. Giordano, G. Barsotti, C. Zecchetto, F. Bergamo, M. Landriscina, M. Masucci, G. Di Paolo, F. De Vita, V. Gebbia, A. Mancino, G. Ricagno, R. Bianco, S. Noventa, G. Lo Re, E. Vasile, S. Sperotto, S. Casalino, V. Merz, S. Lonardi
Journal: Annals of Oncology (2024)
361P Modified FOLFIRINOX as second-line therapy in 140 patients with pancreatic adenocarcinoma patients who have failed first-line treatment using gemcitabine and nab-paclitaxel
Authors: D. Farrell, S. Fitzgerald, A. Daly, B. Knox, J. Divilly, M. Robinson, L. Gallagher, P. Burke, A. Dean
Journal: Annals of Oncology (2024)
501TiP Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma
Authors: K. Shitara, P.C. Enzinger, A.S. Mohapatra, Y.Y. Janjigian
Journal: Annals of Oncology (2024)
LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Authors: K. Shitara, S.Y. Rha, L.S. Wyrwicz, T. Oshima, N. Karaseva, M. Osipov, H. Yasui, H. Yabusaki, S. Afanasyev, Y-K. Park, S-E. Al-Batran, T. Yoshikawa, P.E. Yanez Weber, M. Di Bartolomeo, S. Lonardi, X. Fang, C-S. Shih, P. Bhagia, Y-J. Bang
Journal: Annals of Oncology (2024)
331P Phase Ib/IIa study to evaluate safety and efficacy of priming treatment with the hedgehog inhibitor NLM-001 prior to gemcitabine and nab-paclitaxel plus zalifrelimab as first-line treatment in patients with advanced pancreatic cancer: NUMANTIA study
Authors: T. Macarulla Mercade, K. McAndrews, R.A. Pazo Cid, L. Medina Rodríguez, A. Gil-Negrete, F. Rivera Herrero, V. Varela Pose, A. Martín-Muñoz, Y. Ruiz-Heredia, R. Kalluri, M. Hidalgo
Journal: Annals of Oncology (2024)
378P First-line systemic treatment outcomes in a real-world advanced pancreatic cancer cohort
Authors: H.A. Tafenzi, Y. Ait Takniouine, E.K. Haag, B.D. Abdillahi, F. Choulli, A. Baladi, I. Essadi, R. Belbaraka
Journal: Annals of Oncology (2024)
521P Risk factors for early discontinuation of anamorelin hydrochloride in patients with cancer cachexia: A multicenter, retrospective cohort study (HGCSG2201)
Authors: K. Harada, S. Kajiura, K. Sawada, K. Hatanaka, A. Sato, K. Ito, H. Tamura, A. Doi, T. Ando, M. Nakamura, H. Nakatsumi, T. Muranaka, S. Sogabe, T. Ishii, S. Nakano, M. Dazai, Y. Sasaki, Y. Kawamoto, S. Yuki, Y. Komatsu
Journal: Annals of Oncology (2024)
374P Insights into treatment modalities and prognostic factors in pancreatic cancer patients: A 5-year real-world data analysis
Authors: A.R.R. Freitas, L. Goncalves, T.S. Martins, R.M. Ferreira, J. Lobato Rosa, A. Zanga, Moeda C., I.M. Sousa, A.F. Chaves, M.C. Silva Sousa, R.S. Vicente, T.F. Da Cruz Tomas
Journal: Annals of Oncology (2024)
327P A strategic combination of induction FOLFIRINOX and chemoradiation in locally advanced pancreatic cancer: A phase II trial
Authors: M. Fiore, G. D’Ercole, G.M. Petrianni, P. Trecca, M. Benincasa, E. Onorati, E. Ippolito, D. Caputo, G. Tonini, R. Coppola, S. Ramella
Journal: Annals of Oncology (2024)
513P The prognostic value of baseline CT-based body composition, functional status, and systemic inflammation in older adults with metastatic gastrointestinal cancers: A pooled analysis of two prospective Nordic cohorts
Authors: G. Liposits, K. Aasebø, A.G. Aker, L. Lähteenmäki, D.T. Alavi, E. Jespersen, J. Ryg, S. Möller, S.B. Winther, S.L. Krogh, M. Harneshaug, H.B. Eggesbø, H. Sorbye, P. Pfeiffer
Journal: Annals of Oncology (2024)
307P Impact of inflammatory index on the prognosis of cholangiocarcinoma in Mexican population
Authors: M. Herrera Martinez, B. Carbajal, P. Juarez Mejia, G. Calderillo Ruiz, M.D.C. Diaz Romero, S. Zilli Hernández, S.M. Miyagui Adame, V. Salais Michaus, J. Cervantes Bojalil, A.W. Saenz Mamani, E. Ruiz
Journal: Annals of Oncology (2024)
499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN PROGRESS)
Authors: E. Smyth, D. Griffiths, K. Cozens, C. Hurt, R. Waugh, R. Turkington, K. Foley, R. Roy, S. Sharma, A. Jurdi, M.C. Liu, S. Ngan, R. Owen, D. Chuter, C. Steel, G. Griffiths
Journal: Annals of Oncology (2024)
510P Feasibility of non-operative management in patients with localized mismatch repair deficient (dMMR) gastrointestinal (GI) cancer receiving immunotherapy (IO)
Authors: S. Chakrabarti, J.E. Selfridge, E. Steinhagen, M. Lumish, D. Bajor, M.L. Conces, A. Mohamed, R. Hoehn, J. Miller-Ocuin, A. Mahipal, A. Shreenivas
Journal: Annals of Oncology (2024)
304P Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors
Authors: S. Casalino, C. Gerdes, A. Saborowski, A. Quinzii, C. Zecchetto, A. Sordo, L. Messineo, L.C. Leta, E. Lucin, L. Mendo, S. Pietrobono, A. Vogel, D. Melisi
Journal: Annals of Oncology (2024)
517P Real-world efficacy and safety of immune checkpoint inhibitors (ICI) in gastrointestinal tumors with mismatch repair deficiency or microsatellite instability (dMMR/MSI-H)
Authors: N. Martinez Lago, A. Cousillas, P. Jara, M. Reboredo López, P. González Villarroel, M. Covela, C. Lopez, B. Grana Suarez, E. Gallardo Martin, J. de la Camara Gomez, C. Garcia Lorenzo, C. Lopez Jato, A. Carral Maseda, A. Fernandez Montes, F. Rivera Herrero
Journal: Annals of Oncology (2024)
325P Losartan plus mFOLFIRINOX versus mFOLFIRINOX in advanced pancreatic adenocarcinomas: A two-arm open label prospective parallel design randomized superiority clinical trial (AFPAC)
Authors: A. Ramaswamy, P.G. Bhargava, V. Gota, S. Mandavkar, P.V. Jadhav, N.S. Sultana, M.S. Vora, H.N. Gujarathi, K.A. Gandhi, S.V. Shrikhande, V. Chaudhari, M. Bhandare, D. Naughane, T. Garkal, V.S. Ostwal
Journal: Annals of Oncology (2024)
516P Immune response to SARS-CoV-2 vaccine in patients (pts) with gastrointestinal (GI) cancers receiving systemic treatment in Immunocovid-19 study
Authors: F. Caputo, M. Rotolo, E. Carretto, L. Albertazzi, G. Ciardiello, S. Cavuto, L. Savoldi, M. Lombardi, S. Soncini, C. Galimberti, M. Perrone, C. Masini, A. Bologna, R. Di Cicilia, M. Banzi, M. Pagano, M. Panebianco, A. Damato, A. Neri, C. Pinto
Journal: Annals of Oncology (2024)
317P Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)
Authors: D. Cowzer, K. Seier, M. Darmofal, P. Shin, D. Khalil, H. Walch, J. Shia, W. Park, I. Eldika, W. Chatila, N. Schultz, A. Wei, A. Cercek, E.M. O'Reilly, D. Solit, M. Gonen, M. Berger, G.K. Abou-Alfa, W. Jarnagin, J.J. Harding
Journal: Annals of Oncology (2024)
356P Late-onset pancreatic cancer (LOPC) patients (pts) treated at an Italian center: A real-word analysis from the Gemelli GENERATOR experience
Authors: A. Cosmai, G. Trovato, F. Minnozzi, M. Bensi, J. Lenkowicz, C. Iacomini, N. Digiorgi, G. Caira, L. Di Francesco, D. Barone, A. Ceccarelli, S. Perazzo, L. Chiofalo, A. Spring, M. Chiaravalli, G. Quero, S. Alfieri, C. Bagalà, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2024)
389P Serum MUC5AC predicts recurrence in pancreatic ductal adenocarcinoma patients on neoadjuvant chemotherapy before resection
Authors: A. Manne, A. Esnakula, T.M. Pawlik, U. Manne, R.K. Paluri, A. Kasi, D. Sohal, M. Khushman, K. He, J. Cloyd, E. Miller, K. Pitter, A.M. Noonan, A. Mittra, P. Malalur, J. Hays, N. Jin, M. Dillhoff, S. Rahman, L. Yu, W. Yang
Journal: Annals of Oncology (2024)
512P Predictive biomarkers and protein specific mismatch repair (MMR) loss in gastrointestinal (GI) tumours on immune checkpoint inhibitors (ICI): Correlation with survival
Authors: H.M.L. Le, R.V.D.S. Paiva, S. Farag, K. Dadouli, P. Ntellas, D. Cunningham, N. Starling, S. Rao, C. Fribbens, I. Chau
Journal: Annals of Oncology (2024)
497TiP Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus trifluridine/tipiracil for pre-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG15822G)
Authors: N. Takahashi, H. Hara, K. Nagashima, K. Hirata, T. Masuishi, T. Matsumoto, H. Kawakami, K. Yamazaki, S. Hironaka, N. Boku, K. Muro
Journal: Annals of Oncology (2024)
371P The role of diabetes as prognostic factor in patients (pts) with pancreatic cancer (PC): A retrospective, single-center analysis
Authors: E. Valenzi, V. Zanuso, A. Pirozzi, G. Tesini, R. Balsano, T. Pressiani, S. Carrara, T. Comito, C. Bonifacio, M. Nebbia, M. Pagnanelli, C. Ridolfi, G. Capretti, F. Gavazzi, G. Nappo, A. Zerbi, S. Bozzarelli, L. Rimassa
Journal: Annals of Oncology (2024)
345P Match-pair analysis of mFOLFIRINOX vs gemcitabine+nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: Survival and toxicity outcomes
Authors: A. Jain, S. Soni, K.R. Domadia, V. Goyal, P. Goyal, S. Narayan, P. Redhu, S.S. Mathighatta Shivarudraiah, R. Anand, V. Talwar
Journal: Annals of Oncology (2024)
522P Intra-arterial hepatic chemotherapy: Role beyond colorectal cancer?
Authors: E.J. El Rawadi, A. Boileve, F.G. Dall'Olio, A. Tarabay, M. Gelli, L. Tselikas, C. Smolenschi, M. Valery, B. Besse, E. Baudin, B. Pistilli, D. Malka, A. Hollebecque, V. Boige, M.P. Ducreux
Journal: Annals of Oncology (2024)
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Authors: Ajit Regmi, Eitaro Aihara, Michael E. Christe, Gabor Varga, Thomas P. Beyer, Xiaoping Ruan, Emily Beebe, Libbey S. O’Farrell, Melissa A. Bellinger, Aaron K. Austin, Yanzhu Lin, Haitao Hu, Debra L. Konkol, Samantha Wojnicki, Adrienne K. Holland, Jessica L. Friedrich, Robert A. Brown, Amanda S. Estelle, Hannah S. Badger, Gabriel S. Gaidosh, Sander Kooijman, Patrick C.N. Rensen, Tamer Coskun, Melissa K. Thomas, William Roell
Journal: Cell Metabolism (2024)
519P The efficacy of oxaliplatin desensitisation protocol in patients with GI malignancies
Authors: E. Christodoulis, P.J. Vlachostergios, J. Connell, J. Williams, J. Hasan, W. Mansoor, S. Mullamitha, R. Hubner, M. Braun, M.P. Saunders, J. Barriuso, T.S. Waddell, N. Alam, K.V. Kamposioras
Journal: Annals of Oncology (2024)
365P Pancreatic cancer in young patients under the age of 45 years old: A comparative study with older patients
Authors: G. Sirine, I. Belaid, S. Maatallah, N. Kooli, E. Boudhina, A. Gammoudi, F. Ezzaairi, K. Khelifi, M. Hochlaf, I. Chabchoub, L. Ben Fatma, M. Elghali, A. Bouazzi, S. Tbessi, N. Abdessayed, D. Chiba, O. Belkacem, A. Guesmi, N. Bouzid, S. Benahmed
Journal: Annals of Oncology (2024)
391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
Authors: J.A. Bridgewater, L. Chantrill, R. Gillmore, R. Hubner, N. Starling, F. Froeling, H.S. Wasan, B. Basu, F. Collison, B. Markman, M. Chisamore, L. Goodwin, D. Wilson, C. Phillips, J. Robertson, H. Timmis, Z. Setchellova, S.A. Woodcock, J.W. Valle
Journal: Annals of Oncology (2024)
335P Management, outcome and prognostic factors of metastatic pancreatic cancer
Authors: S. Maatallah, I. Belaid, G. Sirine, A.W. Ben Naya, N. Kooli, A. Gammoudi, F. Ezzaairi, K. Khelifi, M. Hochlaf, I. Chabchoub, L. Ben Fatma, M. Elghali, A. Bouazzi, S. Tbessi, N. Abdessayed, D. Chiba, O. Belkacem, A. Guesmi, N. Bouzid, S. Benahmed
Journal: Annals of Oncology (2024)
323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3
Authors: T. Macarulla Mercade, R.A. Pazo Cid, M. Womack, A. Cubillo Gracian, A. Zervoudakis, H. Hatoum, V. Chung, A. Patel, A.S. Paulson, S. Pant, E.M. O'Reilly, R. Hubner, E. Van Cutsem, T. Bekaii-Saab, L. Zhang, J. Li, H. Chen, F. Maxwell, Z.A. Wainberg, D. Melisi
Journal: Annals of Oncology (2024)
504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)
Authors: Z.A. Wainberg, A.H. Bent, V. Moreno, M. Pedregal, R. Mehta, E.X. Chen, J.L. Ramón Patino, R.H. Moy, B. Madajewski, A. Petrone, P. Adesara-Patel, Y. Liu, X. Sun, E. Aguado-Fraile, P.A. Basciano, S. Sethuraman, N. Hawkey, E. Fontana
Journal: Annals of Oncology (2024)
377P Prognostic model and treatment outcomes in elderly patients with metastatic pancreatic cancer
Authors: M. Mariam, I. Bazin, D. Kantieva, Y. Chikhareva, K. Galanova, G. Naydin, G.G. Makiev, R.R. Abdulaeva, A. Tryakin
Journal: Annals of Oncology (2024)
326P NeoPancONE: Feasibility of completing a neoadjuvant multicentre phase II study in resectable pancreatic ductal adenocarcinoma (r-PDAC), treated with modified FOLFIRINOX (mFFX)
Authors: R.A. McLaughlin, Z. Coyne, D. Jonker, P. Karanicolas, S. Hakim, S. Welch, D.J. Renouf, K. Bertens, C-A. Moulton, M. Raphael, S. Jayaraman, M. Moore, E. Elimova, N. Coburn, J. Abou-Khalil, K. Khalili, S.E. Fischer, A. Dodd, S. Gallinger, J.J. Knox
Journal: Annals of Oncology (2024)
310P Pattern of care and outcomes in periampullary carcinoma in the Indian Subcontinent: A retrospective observational study
Authors: K. Jayalingappa, A. Sehrawat, P. Kumar, D. Sundriyal, A. Gupta, S.S. Panda, R. Singhal, A. Sanyal, N. Arumugam, K.K. Rathnam, S.V. Saju, H.S. Raju, S. Natarajan, S. Subhashree, M.K. Selvaraj, M. Sajid
Journal: Annals of Oncology (2024)
352P Germline profiling of pancreatic cancer in a Middle Eastern population: A comprehensive cancer center prospective study
Authors: R. Amarin, Y. Saleh, H. Bani Hani, A. Al-Atary, S. Khater, T. Al-Batsh, B.S. Sharf, A. Zayed, S. Mahafdah, L. Ababneh, Y. Almasri, T. Alawabdeh, H. Abdel-Razeq
Journal: Annals of Oncology (2024)
324P Effect of NALIRIFOX in Asian patients (pts) with treatment-naive metastatic pancreatic adenocarcinoma (mPAC): Results from the NAPOLI 3 trial
Authors: W. Lee, I-H. Kim, S.C. Oh, C. Lomma, T. Macarulla Mercade, A. Zervoudakis, B. Vicuna, K. Sampat, A. Bullock, E. Segelov, A.S. Paulson, J. Peguero, H. Hassan, F. Delaporte, L. Martin Fernandez, N. Causse-Amellal, D. Melisi
Journal: Annals of Oncology (2024)
494TiP Efficacy and safety of cadonilimab and COX-2 inhibitor combined with oxaliplatin and capecitabine (XELOX) in perioperative treatment for locally advanced resectable gastric adenocarcinoma: A prospective, single-center, randomized, phase II trial
Authors: Y. Qian, E. Zhai, J. Ye, S. Chen, K. Yuan, Z. Wang, J. Xu, X. Zhang, J. Ma, C. Chen, J. Peng, J. Chen, S. Cai
Journal: Annals of Oncology (2024)
525P Prevalence of UGT1A1*28 promoter polymorphism in the omani population: Implications for irinotecan treatment in GI cancer
Authors: A.A.G. Al Ghoche, S. Al Zadjali, A. Pullanhi, A. Alfahdi, A. Al-Balushi, N. Al-Mahrouqi, R. Abu Omar, B. Salman, M. Almoundhri
Journal: Annals of Oncology (2024)
372P Third-line (3L) single-agent chemotherapy (single-CTx) versus combination chemotherapy (combo-CTx) for patients (pts) with advanced pancreatic cancer (aPC): A retrospective, single-center study
Authors: A. Pirozzi, V. Zanuso, G. Tesini, E. Valenzi, R. Balsano, T. Pressiani, F. Gavazzi, A. Zerbi, S. Bozzarelli, L. Rimassa
Journal: Annals of Oncology (2024)
309P Cholangiocarcinoma (CCA) in patients treated across lower Austria: A multicenter retrospective study
Authors: D-C. Morariu-Marina, M. Doeger, T. Pazitny, M. Bachner, K. Müllner, V. Felsleitner-Hauer, G. Engelich, L. Krammer, B. Grünberger
Journal: Annals of Oncology (2024)
328P Trifluridine/tipiracil (FTD/TPI) in patients with fluoropyrimidine refractory advanced pancreatic adenocarcinoma: A single-arm phase II trial
Authors: C-L. Chiang, S.K. Chan, A.S. Lee, C.Y. Wong, D. Chan, W.H.K. Chiu, R. Lo
Journal: Annals of Oncology (2024)
318P Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study
Authors: M. Salati, M.P.F. Quitadamo, L. Moscetti, F. Gelsomino, A. Spallanzani, A. Barbato, C. Pollastro, L. Evangelista, P. Pisapia, U. Malapelle, G. Luppi, S. Benatti, L. Reggianibonetti, G. Troncone, B. Franco, M. Dominici, P. Carotenuto
Journal: Annals of Oncology (2024)
518P Genetic and clinical characterization of Guatemalan patients with Lynch syndrome-related cancers
Authors: J.F. Alvarado Muñoz, A.A. Oliva, M.I. Fuentes-Merlos, V.M. Alvarado, M. Villegas, S. Torselli, A.M. Reyes Morales, B.N. Ramirez
Journal: Annals of Oncology (2024)
502TiP Design and rationale of the PROSPECTive evaluation of nivolumab in adjuvant esophageal cancer/gastroesophageal junction cancer (EC/GEJC) (PROSPECT-ESO): A prospective, non-interventional, multicentre cohort study
Authors: M.A. Shah, A. Saeed, S. Kakehi, R.J. Kelly, K. Kondo, M. Herber, A. Stein, Z. Khan, I. Sestak, Y. Halchenko, C. Davis, P. Singh
Journal: Annals of Oncology (2024)
529P Development and validation of a high-throughput drug screen (HTDS) from patient-derived tumor organoids (PDTO) from gastrointestinal malignancies: Clinical and genomic correlations
Authors: U. Khan, S. Singh, I. Us, S. Sarkar, T. Alban, T. Chan, E. Hissong, B. Bhinder, J. Moyer, L. Martin, M.A. Shah
Journal: Annals of Oncology (2024)
348P Early-onset pancreatic cancer (EOPC) patients (pts) treated at an Italian third level referral center: A real-word artificial-intelligence (AI) analysis from the Gemelli Generator experience
Authors: L. DiFrancesco, G. Trovato, F. Minnozzi, M. Bensi, G. Caira, A. Cosmai, D. Barone, A. Ceccarelli, S. Perazzo, L. Chiofalo, A. Spring, M. Chiaravalli, G. Quero, S. Alfieri, C. Bagalà, G. Tortora, L. Salvatore, J. Lenkowicz, C. Iacomini, N. Digiorgi
Journal: Annals of Oncology (2024)
344P Survival predictors in pancreatic cancer patients on liposomal irinotecan plus fluorouracil/leucovorin: A multicenter observational study
Authors: J. Keum, H.S. Lee, C.S. Park, J. Kim, W. Jang, K.I. Shin, H. Kang, S.H. Lee, J.H. Jo, S-I. Jang, M.J. Chung, J.Y. Park, S.W. Park, J.H. CHO, S. Bang
Journal: Annals of Oncology (2024)
357P Single-center analysis of DNA damage repair (DDR) germline mutations (GM) in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Authors: G. Trovato, M. Bensi, D. Barone, M. Chiaravalli, A. Cosmai, L. Di Francesco, A. Spring, G. Quero, S. Alfieri, C. Bagalà, D. Giannarelli, A. Minucci, A. Urbani, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2024)
341P Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine + nab-paclitaxel and second-line nanoliposomal-irinotecan + 5-FU/leucovorin
Authors: T. Sanomachi, A. Ohba, N. Ogura, H. Hara, S. Yagi, M.O. Okada, Y. Maruki, Y. Nagashio, S. Kondo, H. Susumu, C. Morizane, H. Ueno, T. Okusaka
Journal: Annals of Oncology (2024)
349P MR-guided stereotactic radiotherapy for pancreatic cancer: Results of a prospective registry study
Authors: M. Shouman, A. Gaasch, S. Boyaci, M.C. Rottler, F. Fuchs, C. Eze, S. Marschner, C.B. Westphalen, D. Andrade, G. Beyer, M. Niyazi, C. Belka, S.D. Corradini, P. Rogowski
Journal: Annals of Oncology (2024)
329P Nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in advanced pancreatic cancer
Authors: E. Van Cutsem, S. Ochsenreither, J.J. Collignon, R.L. Eefsen, A. Ivanauskas, C. Rydberg-Millrud, N. Losic, D. Tersago
Journal: Annals of Oncology (2024)
376P FOLFIRINOX vs gemcitabine nab-paclitaxel: A real-world efficacy and safety analysis - a single-centre experience
Authors: A.M. Khan, S. Noor, R. Ahmed, S. Takreem, S.S. Shahnoor, V.K. Muddu, A. Bonda, I. Siripurapu, S. Krishnaiah, G. Rao, N. Reddy
Journal: Annals of Oncology (2024)
LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial
Authors: D. Tougeron, J.F. Emile, A. Bodere, E. Barbier, J. Bez, L.M. Dourthe, H. Perrier, S. Corbinais, V. Le Brun-Ly, K. Bideau, B. Chibaudel, F. Khemissa, J. Hartwig, M. Laly, A. Lievre, C. Toullec, M. Muller, P. Laurent-Puig, C. Lepage, J. Taieb
Journal: Annals of Oncology (2024)
520P Guidelines for time-to-event endpoints in gastrointestinal cancer using real-world data
Authors: P. Vissers, M.A.G. Elferink, B. Bonsing, L. Vandergeest, M. Koopman, H.W.M. van Laarhoven, G. Nieuwenhuijzen, P.S.N. van Rossum, F.P.C. Sijtsma, G.R. Vink, J. de vos-Geelen, H. Wilmink, H. Dewilt, R.H.A. Verhoeven, F.N. van Erning
Journal: Annals of Oncology (2024)
336P Modified technique of duct to mucosa pancreaticojejunal anastomosis in Whipple`s pancreatoduodenectomy outcomes of a novel technique
Authors: V. Vijayakumar, R. E, B. M, P. S, S. Deen, B. Venkitaraman, S. Narayanan, J. Chandrabose
Journal: Annals of Oncology (2024)
500TiP An open label phase Ib/II study of trastuzumab deruxtecan (T-DXd) in combination with nivolumab and CAPOX for patients with HER2-low expressing gastroesophageal adenocarcinoma (EPOC2203)
Authors: Y. Aoki, I. Nakayama, S. Fukuoka, H. Shoji, M. Furuta, K. Minashi, H. Hara, M. Wakabayashi, Y. Komura, A. Sato, N. Fuse, N. Sakamoto, T. Kuwata, K. Shitara
Journal: Annals of Oncology (2024)
346P Final results of multicenter prospective observational study of nano-liposomal irinotecan, fluorouracil and folinic acid in second-line chemotherapy for advanced pancreatic cancer: The NAPOLEON-2
Authors: K. Toyodome, S. Arima, M. Shimokawa, T. Otsuka, J. Nakazawa, H. Shimokawa, F. Koga, H. Oda, S. Takeshita, Y. Kawaguchi, S. Arita, K. Nishikawa, K. Jikuya, T. Sakai, H. Sawase, Y. Ueda, N. Araki, T. Shirakawa, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2024)
367P Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study
Authors: P. Cerda Serda, B. Martin Cullell, F. Castet, A. Pisa Gatell, P. Ribera Fernandez, J. Fernandez, T. Sauri Nadal, F.J. Pelegrín Mateo, M. Aguado Sorolla, T. Ramon Y Cajal
Journal: Annals of Oncology (2024)
LBA4 Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial
Authors: G. Randon, F. Nappo, M. Fassan, S. Tamberi, E. Giommoni, S. Di Donato, L. Fornaro, O. Brunetti, F. De Vita, G.L. Frassineti, C. Chini, A. Spallanzani, V. Bethaz, A. Strippoli, T.P. Latiano, G. Cardellino, C. Ceccon, F. Palermo, M. Di Bartolomeo, F. Pietrantonio
Journal: Annals of Oncology (2024)
313P Disease and treatment patterns for advanced cholangiocarcinoma: A multicentric study from Portugal
Authors: J.C.N. Gonçalves, A.R.R. Freitas, A.R. Fortuna, M.B. Menezes, J. Gramaça, I.C. Gomes Fernandes, I.C. Angelo, C.F.P. Trabulo, C. Xavier de Sousa, I.M. Matos Pina
Journal: Annals of Oncology (2024)
498TiP Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial
Authors: V. Nasca, A. Raimondi, F. Palermo, F. Morano, F. Bergamo, L. Foltran, A. Spallanzani, O. Brunetti, D. Spada, S. Tamberi, L. Antonuzzo, C.A. Cella, A. Avallone, K. Bencardino, L. Fornaro, S. Di Donato, A. Strippoli, A. Puccini, E. Tamburini, F. Pietrantonio
Journal: Annals of Oncology (2024)
505P State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR)
Authors: R. Fazio, A. Audisio, E.D. Saad, G. Bregni, D. Sur, V. Daprà, C. Conti, F-Z. Abbassi, N. Benhima, I. Assaf, A. Hendlisz, J-L. van Laethem, F. Sclafani
Journal: Annals of Oncology (2024)